Showing results (191-200 of 211) with videos related to
Sort By:
Pageof 22
Bioorganic & Medicinal Chemistry Letters|February 23, 2008
Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazolesRichard C A Isaacs, Mark G Solinsky, Kellie J Cutrona, et al.The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the ratE A Kowaluk, J Mikusa, C T Wismer, et al.The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosisJ J Cook, S J Gardell, M A Holahan, et al.Journal of Medicinal Chemistry|July 8, 1999
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregationM S Egbertson, J J Cook, B Bednar, et al.The Spine Journal : Official Journal of the North American Spine Society|October 27, 2023
Early versus late surgical decompression for patients with acute traumatic central cord syndrome: a systematic review and meta-analysisShahab Aldin Sattari, Albert Antar, John N Theodore, et al.IEEE Transactions on Bio-Medical Engineering|April 5, 2023
Low-Intensity Pulsed Ultrasound Neuromodulation of a Rodent's Spinal Cord Suppresses Motor Evoked PotentialsYohannes Tsehay, Yinuo Zeng, Carly Weber-Levine, et al.The Journal of Pharmacology and Experimental Therapeutics|November 14, 1997
Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptorS Patel, S Freedman, K L Chapman, et al.Journal of Medicinal Chemistry|November 14, 1997
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 positionT J Tucker, W C Lumma, S D Lewis, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 1999
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorptionR C Isaacs, K J Cutrona, C L Newton, et al.The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217J J Cook, M A Holahan, E A Lyle, et al.Pageof 22